You are here: Home » International » News » Economy
Business Standard

China's global Covid-19 vaccination program may face production problems

China vaccination program faces production problems with an expert believing it to be inadequate to satisfy the domestic and international demand

Topics
China | Coronavirus Vaccine

ANI 

Covid-19, coronavirus, vaccine-themed pastry, sweet mousses, hungary
Photo: Twitter

Though China's drive to vaccinate its population with home-made COVID-19 vaccines is being extended to as many as 30 countries around the world, the program faces production problems with an expert believing it to be inadequate to satisfy the domestic and demand.

According to South Morning Post (SCMP), the so-called Spring Seedling Action program, announced in March by Foreign Minister Wang Yi, claims to avail vaccinations supplied by Beijing to tens of millions of Chinese nationals living overseas.

However, it is not clear if will be able to produce enough to meet demand at home and abroad.

Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations in New York, said: "The problem is that it currently does not have enough production capacity to satisfy both domestic and demand, which makes its vaccine diplomacy unsustainable at least in the coming two months."

Yin Weidong, the chairman of vaccine maker Sinovac Biotech, said last month that there was a shortage of COVID-19 jabs in

Meanwhile, health authorities in Sri Lanka approved Sinopharm's vaccine for local emergency use, however, it has come under intense criticism for being available only for Chinese nationals in the country, SCMP reported.

The country has set a target of vaccinating 40 per cent of the population - 560 million people - by June. However, experts believe it is unlikely to reach the target due to production problems.

Another problem was that its vaccines had relatively low efficacy rates, which meant a larger number of people would have to be vaccinated for the country to reach herd immunity, said Nicholas Thomas, an associate professor in the Asian and studies department at City University of Hong Kong.

"The parallel challenge for China is that it needs to have a much larger percentage of its population vaccinated if it is to reopen its borders for both inbound and outbound tourism and trade," he said.

Concerns over the efficacy of Chinese vaccines and repeated delays of shipments to other nations are denting their fight against COVID-19.

This is better exemplified when parts of Turkey's vaccination network almost came to a halt as hospitals and clinics were forced to turn away patients, Washington Post reported citing Sebnem Korur Fincanci, president of the Turkish Medical Association. China's efforts have also been hampered by the refusal of its pharmaceutical companies to release data on the efficacy of their vaccines.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, May 03 2021. 12:29 IST
RECOMMENDED FOR YOU
.